{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T02:40:55Z","timestamp":1775616055600,"version":"3.50.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,7,8]],"date-time":"2020-07-08T00:00:00Z","timestamp":1594166400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,7,8]],"date-time":"2020-07-08T00:00:00Z","timestamp":1594166400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin J Gastroenterol"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1007\/s12328-020-01178-5","type":"journal-article","created":{"date-parts":[[2020,7,8]],"date-time":"2020-07-08T21:02:53Z","timestamp":1594242173000},"page":"1310-1314","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Pembrolizumab-induced sclerosing cholangitis in a lung adenocarcinoma patient with a remarkable response to chemotherapy: a case report"],"prefix":"10.1007","volume":"13","author":[{"given":"Kentaro","family":"Sato","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2213-3918","authenticated-orcid":false,"given":"Manabu","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazumichi","family":"Abe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masashi","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiromasa","family":"Ohira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,7,8]]},"reference":[{"key":"1178_CR1","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/nrclinonc.2016.58","volume":"13","author":"C Boutros","year":"2016","unstructured":"Boutros C, Tarhini A, Routier E, et al. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Nat Rev Clin Oncol. 2016;13:473\u201386.","journal-title":"Nat Rev Clin Oncol"},{"key":"1178_CR2","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","volume":"378","author":"MA Postow","year":"2018","unstructured":"Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378:158\u201368.","journal-title":"N Engl J Med"},{"key":"1178_CR3","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1001\/jamaoncol.2017.2925","volume":"4","author":"K Haratani","year":"2018","unstructured":"Haratani K, Hayashi H, Chiba Y, et al. Association of Immune-related adverse events with nivolumab efficacy in non-small-cell lung cancer. JAMA Oncol. 2018;4:374\u20138.","journal-title":"JAMA Oncol"},{"key":"1178_CR4","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1002\/hep.21405","volume":"44","author":"R Abdalian","year":"2006","unstructured":"Abdalian R, Heathcote EJ. Sclerosing cholangitis: a focus on secondary causes. Hepatology. 2006;44:1063\u201374.","journal-title":"Hepatology"},{"key":"1178_CR5","doi-asserted-by":"crossref","first-page":"353","DOI":"10.3748\/wjg.v26.i3.353","volume":"26","author":"T Onoyama","year":"2020","unstructured":"Onoyama T, Takeda Y, Yamashita T, et al. Programmed cell death-1 inhibitor-related sclerosing cholangitis: a systematic review. World J Gastroenterol. 2020;26:353\u201365.","journal-title":"World J Gastroenterol"},{"key":"1178_CR6","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1111\/hepr.13329","volume":"49","author":"Y Koya","year":"2019","unstructured":"Koya Y, Shibata M, Shinohara N, et al. Secondary sclerosing cholangitis with hemobilia induced by pembrolizumab: case report and review of published work. Hepatol Res. 2019;49:950\u20136.","journal-title":"Hepatol Res"},{"key":"1178_CR7","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ctrv.2016.02.001","volume":"44","author":"L Spain","year":"2016","unstructured":"Spain L, Diem S, Larkin J. Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev. 2016;44:51\u201360.","journal-title":"Cancer Treat Rev"},{"key":"1178_CR8","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s00535-020-01677-9","volume":"55","author":"K Mizuno","year":"2020","unstructured":"Mizuno K, Ito T, Ishigami M, et al. Real world data of liver injury induced by immune checkpoint inhibitors in Japanese patients with advanced malignancies. J Gastroenterol. 2020;55:653\u201361.","journal-title":"J Gastroenterol"},{"key":"1178_CR9","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1002\/hep.30189","volume":"69","author":"K Ogawa","year":"2019","unstructured":"Ogawa K, Kamimura K, Terai S. Antiprogrammed cell death-1 immunotherapy-related secondary sclerosing cholangitis. Hepatology. 2019;69:914\u20136.","journal-title":"Hepatology"},{"key":"1178_CR10","doi-asserted-by":"crossref","first-page":"E259","DOI":"10.1055\/a-0640-2392","volume":"50","author":"N Kuraoka","year":"2018","unstructured":"Kuraoka N, Hara K, Terai S, et al. Peroral cholangioscopy of nivolumab-related (induced) ulcerative cholangitis in a patient with non-small cell lung cancer. Endoscopy. 2018;50:E259\u201361.","journal-title":"Endoscopy"},{"key":"1178_CR11","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s10637-017-0453-0","volume":"35","author":"H Kawakami","year":"2017","unstructured":"Kawakami H, Tanizaki J, Tanaka K, et al. Imaging and clinicopathological features of nivolumab-related cholangitis in patients with non-small cell lung cancer. Invest New Drugs. 2017;35:529\u201336.","journal-title":"Invest New Drugs"},{"key":"1178_CR12","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s00262-017-2062-3","volume":"67","author":"J Kashima","year":"2018","unstructured":"Kashima J, Okuma Y, Shimizuguchi R, et al. Bile duct obstruction in a patient treated with nivolumab as second-line chemotherapy for advanced non-small-cell lung cancer: a case report. Cancer Immunol Immunother. 2018;67:61\u20135.","journal-title":"Cancer Immunol Immunother"},{"key":"1178_CR13","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.2169\/internalmedicine.1981-18","volume":"58","author":"M Kono","year":"2019","unstructured":"Kono M, Sakurai T, Okamoto K, et al. Efficacy and safety of chemotherapy following anti-PD-1 antibody therapy for gastric cancer: a case of sclerosing cholangitis. Intern Med. 2019;58:1263\u20136.","journal-title":"Intern Med"},{"key":"1178_CR14","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.2169\/internalmedicine.2330-18","volume":"58","author":"K Sawada","year":"2019","unstructured":"Sawada K, Shonaka T, Nishikawa Y, et al. Successful treatment of nivolumab-related cholangitis with prednisolone: a case report and review of the literature. Intern Med. 2019;58:1747\u201352.","journal-title":"Intern Med"},{"key":"1178_CR15","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S1074-7613(04)00050-0","volume":"20","author":"H Dong","year":"2004","unstructured":"Dong H, Zhu G, Tamada K, et al. B7\u2013H1 determines accumulation and deletion of intrahepatic CD8(+) T lymphocytes. Immunity. 2004;20:327\u201336.","journal-title":"Immunity"},{"key":"1178_CR16","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1186\/s40425-019-0779-6","volume":"7","author":"P Xing","year":"2019","unstructured":"Xing P, Zhang F, Wang G, et al. Incidence rates of immune-related adverse events and their correlation with response in advanced solid tumours treated with NIVO or NIVO+IPI: a systematic review and meta-analysis. J Immunother Cancer. 2019;7:341.","journal-title":"J Immunother Cancer"},{"key":"1178_CR17","doi-asserted-by":"crossref","first-page":"e679","DOI":"10.1634\/theoncologist.2019-0299","volume":"25","author":"H Akamatsu","year":"2020","unstructured":"Akamatsu H, Murakami E, Oyanagi J, et al. Immune-related adverse events by immune checkpoint inhibitors significantly predict durable efficacy even in responders with advanced non-small cell lung cancer. Oncologist. 2020;25:e679\u2013e683683.","journal-title":"Oncologist"},{"key":"1178_CR18","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s12967-018-1467-x","volume":"16","author":"S Valpione","year":"2018","unstructured":"Valpione S, Pasquali S, Campana LG, et al. Sex and interleukin-6 are prognostic factors for autoimmune toxicity following treatment with anti-CTLA4 blockade. J Transl Med. 2018;16:94.","journal-title":"J Transl Med"},{"key":"1178_CR19","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1093\/hmg\/ddq551","volume":"20","author":"Y Okada","year":"2011","unstructured":"Okada Y, Takahashi A, Ohmiya H, et al. Genome-wide association study for C-reactive protein levels identified pleiotropic associations in the IL6 locus. Hum Mol Genet. 2011;20:1224\u2013311.","journal-title":"Hum Mol Genet"}],"container-title":["Clinical Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-020-01178-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12328-020-01178-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-020-01178-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,8]],"date-time":"2021-07-08T00:03:00Z","timestamp":1625702580000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12328-020-01178-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,8]]},"references-count":19,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1178"],"URL":"https:\/\/doi.org\/10.1007\/s12328-020-01178-5","relation":{},"ISSN":["1865-7257","1865-7265"],"issn-type":[{"value":"1865-7257","type":"print"},{"value":"1865-7265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,8]]},"assertion":[{"value":"12 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"All procedures followed were performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human\/animal rights"}},{"value":"Informed consent was obtained from the patient for inclusion in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}